Medical specialists from France tagged as investigators in clinical trials studying Primary Myelofibrosis

Total 75 results

Alain Radwan SAAD, PH
Seen in:
- Béziers, CH de Béziers
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Amélie PENOT, PH
Seen in:
- Limoges, CHU de Limoges - Hôpital Dupuytren
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Anaïse BLOUET, PH
Seen in:
- Strasbourg, Clinique Sainte Anne Strasbourg
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Annalisa ANDREOLI, PH
Seen in:
- Argenteuil, CH d'Argenteuil
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Anne PARRY, PH
Seen in:
- Annecy, CH d'Annecy
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Antoine MACHET, Dr
Seen in:
- Tours, CHRU Tours - Hopital Bretonneau
- Tours, CHU de Tours
- Tours, Hôpital Bretonneau
Trials:
- NCT05710211 (Principal Investigator)
- NCT04603495 (Principal Investigator)
- NCT05198960 (Principal Investigator)
Conditions:
Axelle LASCAUX, PH
Seen in:
- Bordeaux, CHU Bordeaux
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Benoît BAREAU, PH
Seen in:
- Cesson-Sévigné, Hôpital privé Cesson-Sévigné
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Benoît DE RENZIS, PH
Seen in:
- Clermont-Ferrand, CHU de Clermont-Ferrand
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Borhane SLAMA, PH
Seen in:
- Avignon, CH d'Avignon
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Boyer-Perrard Francoise
Seen in:
- Pays De La Loire, Angers, Centre hospitalier universitaire d'Angers
Trials:
- NCT04562389 (Principal Investigator)
Conditions:
- Myelofibrosis
Bruno VILLEMAGNE, PH
Seen in:
- La Roche-sur-Yon, Chd Vendee La Roche Sur Yon
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Charles BESCOND, Dr
Seen in:
- Cholet, Ch Cholet
Trials:
- NCT05710211 (Principal Investigator)
Conditions:
- Myelofibrosis
Christophe NICOL, PH
Seen in:
- Morlaix, CH de Morlaix
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Claire CALMETTE, PH
Seen in:
- Périgueux, CH de Périgueux
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Clémence MEDIAVILLA, PH
Seen in:
- Bordeaux, CHU Bordeaux
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Corentin Orvain
Seen in:
- Angers, CHU d'Angers
- Angers, Chu Angers
Trials:
- NCT03869476 (Sub-Investigator)
- NCT05710211 (Principal Investigator)
- NCT05198960 (Principal Investigator)
Conditions:
Damien Luque Paz
Seen in:
- Angers, Chu Angers
Trials:
- NCT03869476 (Principal Investigator)
Conditions:
Dana Ranta, MD
Seen in:
- Nancy, Chu de Nancy
- Vandœuvre-lès-Nancy, Chru Brabois
Trials:
- NCT04603495 (Principal Investigator)
- NCT05198960 (Principal Investigator)
Conditions:
Diane LARA, PH
Seen in:
- Libourne, Ch Libourne
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Emilie CHALAYER, PH
Seen in:
- Saint-Priest-en-Jarez, Institut de Cancérologie Lucien Neuwirth St-Priest-en-Jarez
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Eric Jourdan, MD
Seen in:
- Nimes, hematology Unit CHU Caremeau
- Nîmes, CHU DE NIMES _Institut de Cancérologie du Gard
Trials:
- NCT01976182 (Principal Investigator)
- NCT04603495 (Principal Investigator)
Conditions:
Eric Lippert
Seen in:
- Brest, CHRU de Brest - Hôpital Morvan
Trials:
- NCT03869476 (Sub-Investigator)
Conditions:
Fabrice JARDIN, PH
Seen in:
- Rouen, Centre Henri Becquerel de Rouen
Trials:
- NCT05198960 (Principal Investigator)
Conditions:
Fiorenza Barraco
Seen in:
- Pierre Benite, Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
Trials:
- NCT04562870 (Principal Investigator)
Conditions:
- Myelofibrosis

Clinical Trials on Primary Myelofibrosis

Assaf-Harofeh Medical Center

Unknown

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis (MRMF01)

Myelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ET

Israel
The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
AbbVie

Recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
AbbVie

Terminated

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Korea, Republic of, South Africa
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Moderate and High Risk Myelofibrosis

China
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany

Medical specialists from France tagged as investigators in clinical trials studying Primary Myelofibrosis

Clinical Trials on Primary Myelofibrosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations